Humira, Enbrel Face Pricing Pressures From Copay Accumulator Programs
Executive Summary
Payer efforts to undercut copay assistance are getting manufacturers’ attention. PhRMA launches ad campaign warning patients that 'middlemen' are 'trying to keep you from reaching your deductible.'
You may also be interested in...
Countering Coupons: Large Employers Will Boost Copay Accumulator Programs In 2021
Annual large US employer health benefits survey also evaluates plans for managing the cost of cell and gene therapies in the coming years, anticipating growing use of outcomes-based contracts, but very limited uptake of payment-over-time models.
Countering Coupons: Large Employers Will Boost Copay Accumulator Programs In 2021
Annual large US employer health benefits survey also evaluates plans for managing the cost of cell and gene therapies in the coming years, anticipating growing use of outcomes-based contracts, but very limited uptake of payment-over-time models.
Copay Accumulator-Type Programs Proposed For ACA Exchange Plans
Annual payment rule for individual and group plans governed by Affordable Care Act proposes excluding drug manufacturer-sponsored copay assistance from out-of-pocket caps and seeks comments on use of reference pricing.